Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PTC THERAPEUTICS, INC. shareholders approved Election of four Class I directors at the 2026-06-02 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-02
Exact text from the filing
The Company held its Annual Meeting on June 2, 2026 (the “Annual Meeting”). The results for the votes regarding each proposal at the Annual Meeting are set forth below.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PTC THERAPEUTICS, INC. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-02 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-02
Exact text from the filing
The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by the Company’s stockholders with 76,170,292 votes “For,” 355,794 votes “Against,” and 15,520 votes “Abstained.”
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PTC THERAPEUTICS, INC. shareholders approved Non-binding advisory proposal on named executive officer compensation at the 2026-06-02 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-02
Exact text from the filing
The non-binding advisory proposal on named executive officer compensation was approved by the Company’s stockholders with 71,166,204 votes “For,” 1,492,801 votes “Against,” 24,290 votes “Abstained,” and 3,858,311 broker non-votes.
View on SEC.gov